http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI1006647-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f861d7dfdde7b233339d4838364a8e8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate | 2010-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5cc78323f2cc5fdc0df3ff765b945bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65145918cf171270a4cde07e07028723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2770006ea4aa4fc1fdb580decc839a3 |
| publicationDate | 2013-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI1006647-A2 |
| titleOfInvention | immunogenic composition for paracoccidioidomycosis using pb40r and pb27r proteins |
| abstract | IMMUNOGENIC COMPOSITION FOR PARACOCCIDIOIDOMICOSIS USING THE Pb4Or AND Pb27r PROTEINS. The present invention describes the development of a therapeutic vaccine that can be used as an adjuvant in the chemotherapeutic treatment of paracoccidioidomycosis (PCM). Such a vaccine reduces the treatment time and the risk of relapse, thus improving the prognosis of patients. This therapeutic vaccine, developed through the combined use of Pb4Or and Pb27r proteins, led to a significant reduction in tissue damage to the lung, spleen and liver of infected mice, reaching undetectable levels of colony-forming units per g of tissue (CFU / g). . |
| priorityDate | 2010-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.